-The Financial Express A mechanism is needed to compensate farmers for not exercising their right to sell productive land but continue to grow foodgrains. India finds itself in a piquant situation. While its population, and with it the number of poor, is growing, its cultivable land is not only shrinking, more worryingly, the economic returns of the agricultural use are diminishing vis-a-vis non-agricultural use. The situation may not be alarming right now,...

-The Times of India MUMBAI: In a move that will disappoint many patients, the government has withdrawn CERTain powers of the drug pricing regulator that allowed it to cap prices of widely prescribed anti-diabetes, cancer, HIV, tuberculosis and cardiac medicines. The National Pharmaceutical Pricing Authority (NPPA) said it is withdrawing "with immediate effect" - a guideline that had allowed it to put price caps on crucial medicines - to comply with a...

-Down to Earth While the state government aims to cut costs, children in remote tribal areas will be most affected After repeatedly putting off a decision on the matter, the Maharashtra government has finally decided to close down some 13,905 schools which have a student count of less than 20. Notices to this effect have already been sent to education officers in the state. Officials in the state's Directorate of Primary Education...

-The Hindu Expected to encourage best performers and inspire others Close on the heels of Prime Minister Narendra Modi announcing the ambitious ‘Clean India' mission, the Union Tourism Ministry on Friday said it was working on a "cleanliness index'' for cities in the country to encourage the best performers and, in turn, inspire others to spruce up. "We are preparing a cleanliness index. The methodology has been drafted and index calculated for six...

-The Business Standard A ray of hope for Indian generic drug makers Gilead Sciences, the California-headquartered biotechnology company, has authorised seven India-based drug makers - Cipla, Ranbaxy, Mylan, Strides Arcolab, Hetero, Cadila Healthcare and Sequent Scientific - to manufacture and sell the generic versions of its hepatitis C medicine, Sovaldi, in 91 developing countries. Earlier in the week, Lupin, the fourth largest Indian drug maker, announced that it will develop and supply...